Collaboration Exclusivity. Upon Lilly selecting a Lilly Target Pair, Zymeworks shall collaborate exclusively with Lilly (and not with any Third Party) with respect to applying the Zymeworks Platform to antibodies Directed To such Lilly Target Pair, until the first to occur of (i) termination of the License for such Lilly Target Pair and (ii) Lilly’s ceasing to actively develop or commercialize Antibodies or Products Directed To such Lilly Target Pair pursuant to this Agreement (such period, the “Collaboration Exclusivity Period”). Moreover, during such period, Zymeworks will also not apply the Zymeworks Platform to antibodies Directed To a Lilly Target Pair other than pursuant to a Research Plan or (b) for internal research pre-approved in writing by Lilly. Exclusivity with respect to antibodies Directed To the Lilly Target Pair under this Section 3.5.2 shall not prevent Zymeworks from developing or commercializing, alone or in collaboration with one or more Third Parties, (a) monovalent antibodies Directed To either Target in the Lilly Target Pair, except as prohibited under Section 3.5.1, or (b) Multi-Specific Antibodies that are Directed To one of the Targets within the Lilly Target Pair and one or more other Targets that are not Targets within the Lilly Target Pair. Provided, however, notwithstanding the foregoing, that under no circumstances, shall Zymeworks use Zymeworks Intellectual Property to make, use, sell, offer to sell or import Antibodies or Products or use any Antibodies to make, use, sell, offer to sell or import other products during the term of this Agreement. For clarity, nothing in this Section 3.5.2 shall grant either Party any rights under any Patent Rights, Know-How or other intellectual property rights Controlled by the other Party or its Affiliates for purposes set forth in this Section 3.5.2.
Collaboration Exclusivity. During the Term of this Agreement, neither Party will engage, on behalf of itself or any other party, in the development or commercialization of antisense compounds targeted to Clusterin other than as provided in this Agreement. *Certain information in this exhibit has been omitted as confidential, as indicated by [***]. This information has been filed separately with the Commission.
Collaboration Exclusivity. In consideration of the sums to be paid to Lynx and the other terms and conditions of this Agreement, the Parties agree that during the Collaboration Term, Lynx will not knowingly utilize the Lynx Technology to collaborate with any Third Parties on Crops, provided that Lynx may do such work with respect to the Co-Exclusive Crop for a single Third Party, currently DuPont. Notwithstanding the foregoing, Lynx shall be free to perform subscription gene sequencing, gene expression analysis and related services on a non-exclusive basis for Third Parties, provided that Lynx notifies such Third Parties that they may not utilize Lynx subscription services for the analysis of DNA samples from Crops except that a single Third Party (currently DuPont) may utilize such services for the Co-Exclusive Crop. Moreover, nothing in this Section 3.6 shall be construed to limit or to restrict Lynx in any way from being able to perform its obligations under the agreements in effect prior to the date of this Agreement with DuPont (Agreement dated October 29, 1998, as amended), BASF AG (agreements dated October 23, 1996 and January 1, 1997, as amended) and Hoechst, whether or not such performance would otherwise be in violation of this Section 3.6.
Collaboration Exclusivity. During the Term of this Agreement, neither Party will engage, on behalf of itself or any other party, in the development or commercialization of antisense compounds targeted to IGFBP-5 and/or IGFBP-2 other than as provided in this Agreement. Notwithstanding the forgoing, OncoGenex retains *Certain information in this exhibit has been omitted as confidential, as indicated by [***]. This information has been filed separately with the Commission. the right to use, have used and to grant limited sublicenses to use OncoGenex’s Product-Specific Technology Patents for research, scholarly and other non-commercial purposes only, and such activities will not be interpreted as a breach of this Agreement. Isis retains the right to use antisense compounds targeted to IGFBP-5 and/or IGFBP-2 or to transfer such antisense compounds to third parties for target validation purposes.
Collaboration Exclusivity. Except as otherwise provided in this Agreement, during the term of this Agreement, the Parties will work exclusively with each other with respect to each Designated Antigen in the Collaboration Field.
Collaboration Exclusivity. During the Term of this Agreement, neither Party nor their Affiliates will (a) engage, on behalf of itself or any other party, in the research, development, manufacture, use, offer for sale, sale or import of Antisense Compounds designed to modulate the Collaboration Gene Targets, or (b) grant to any Third Party any license or right to research, develop, make, have made, use, sell, offer for sale, have sold or import Products, other than as provided in this Agreement. Notwithstanding the foregoing, (i) OncoGenex retains the right (A) to use, have used and *Certain information in this exhibit has been omitted as confidential, as indicated by [***]. This information has been filed separately with the Commission. to grant limited sublicenses to use OncoGenex’s Product-Specific Technology Patents for research, scholarly and other non-commercial purposes only and, (B) to grant sublicenses to any Third Party in accordance with Section 3.1.1; and; (ii) Isis retains the right to use Antisense Compounds modulating the Collaboration Gene Targets or to transfer such Antisense Compounds to third parties for non-commercial target validation purposes. In each case such activities will not be interpreted as a breach of this Agreement. In addition, the Parties acknowledge that Isis entered into a Strategic Collaboration and License Agreement with Alnylam Pharmaceuticals, Inc. dated March 11, 2004 and that Alnylam may independently discover and develop Antisense Compounds against Collaboration Gene Targets; however, Isis will not grant Alnylam any Isis Patent Rights specifically claiming the applicable Collaboration Gene Target or methods of specifically treating such Collaboration Gene Target.
Collaboration Exclusivity. Save for only such activities, personnel, resources and facilities of any Affiliate of a Party that, prior to it’s becoming an Affiliate of such Party, have been made subject to a binding commitment that would conflict with such Affiliate’s performance of the exclusivity requirements set forth in this Section 2.1, below:
Collaboration Exclusivity
